Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies
In conclusion, this analysis supports the risk-reduction benefits of riociguat in patients with PAH at intermediate-low risk and intermediate-high risk, and externally validated the utility of COMPERA 2.0 in the long-term risk assessment of patients from a clinical trial population.
Authors
- David Langleben (ORCID: https://orcid.org/0000-0002-6495-0094)
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Claudia Rahner
- Stephan Rosenkranz (ORCID: https://orcid.org/0000-0001-6237-1470)
- David B. Badesch
- Jean‐François Richard (ORCID: https://orcid.org/0000-0003-4750-4380)
- Marc Humbert (ORCID: https://orcid.org/0000-0003-0703-2892)
- Hossein Ardeschir Ghofrani (ORCID: https://orcid.org/0000-0002-2029-4419)
- John W. McConnell
- Sara Hegab
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Bayer (United States) (US)
- Inserm (FR)
- University of Cologne (DE)
- Norton Healthcare (US)
- Université Paris-Saclay (FR)
- Jewish General Hospital (CA)
- Medizinische Hochschule Hannover (DE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hypertension pulmonaire : physiopathologie et innovation thérapeutique (FR)
- Universities of Giessen and Marburg Lung Center (DE)
- Kerckhoff Klinik (DE)
- Deutsche Montan Technologie (Germany) (DE)
- University Hospital Cologne (DE)
- Bicêtre Hospital (FR)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Respiratory Medicine
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1016/j.rmed.2024.107910
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Bayer